AU2003243058A1 - Methods for using the cd163 pathway for modulating an immune response - Google Patents

Methods for using the cd163 pathway for modulating an immune response

Info

Publication number
AU2003243058A1
AU2003243058A1 AU2003243058A AU2003243058A AU2003243058A1 AU 2003243058 A1 AU2003243058 A1 AU 2003243058A1 AU 2003243058 A AU2003243058 A AU 2003243058A AU 2003243058 A AU2003243058 A AU 2003243058A AU 2003243058 A1 AU2003243058 A1 AU 2003243058A1
Authority
AU
Australia
Prior art keywords
pathway
modulating
methods
immune response
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003243058A
Other languages
English (en)
Other versions
AU2003243058A8 (en
Inventor
Louis Boon
Petrus Johannes Simons
David Speijer
Ruprecht Jules Joost Van Neerven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOCEROS BV
Macrozyme BV
Original Assignee
BIOCEROS I O BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02077071A external-priority patent/EP1367393A1/fr
Application filed by BIOCEROS I O BV filed Critical BIOCEROS I O BV
Publication of AU2003243058A8 publication Critical patent/AU2003243058A8/xx
Publication of AU2003243058A1 publication Critical patent/AU2003243058A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003243058A 2002-05-27 2003-05-27 Methods for using the cd163 pathway for modulating an immune response Abandoned AU2003243058A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38368902P 2002-05-27 2002-05-27
EP02077071A EP1367393A1 (fr) 2002-05-27 2002-05-27 Procédé d'utilisation de la voie CD 163 pour la modulation d'une réponse Immunitaire
EP02077071.5 2002-05-27
US60/383,689 2002-05-27
PCT/NL2003/000395 WO2003100419A1 (fr) 2002-05-27 2003-05-27 Procedes d'utilisation de la voie de cd163 pour moduler une reponse immunitaire

Publications (2)

Publication Number Publication Date
AU2003243058A8 AU2003243058A8 (en) 2003-12-12
AU2003243058A1 true AU2003243058A1 (en) 2003-12-12

Family

ID=29585706

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003243058A Abandoned AU2003243058A1 (en) 2002-05-27 2003-05-27 Methods for using the cd163 pathway for modulating an immune response

Country Status (2)

Country Link
AU (1) AU2003243058A1 (fr)
WO (1) WO2003100419A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1660133B1 (fr) * 2003-05-15 2018-04-18 Therapure Biopharma Inc. Administration ciblée de composés antiviraux au moyen de bioconjugués a base d'hémoglobine
ES2530694T3 (es) * 2004-04-23 2015-03-04 Zoetis P & U Llc Factor de permisividad celular para virus, y usos del mismo
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (fr) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) * 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
KR20220035452A (ko) 2019-07-19 2022-03-22 온코리스폰스 인크. 면역조절 항체 및 이의 사용 방법
EP4028029A4 (fr) * 2019-09-09 2023-09-20 The Children's Hospital of Philadelphia Compositions et méthodes de traitement de troubles associés à un dysfonctionnement ou à une perte de clec16a
US20230381334A1 (en) * 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444082T1 (de) * 2000-10-16 2009-10-15 Cytoguide Aps Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür

Also Published As

Publication number Publication date
AU2003243058A8 (en) 2003-12-12
WO2003100419A1 (fr) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2003249333A1 (en) Device interaction
AU2003221662A1 (en) Method for operating an appliance that uses the method
AU2003263867A1 (en) Free fall simulator
AU2003244499A1 (en) Support for multiple login methods.
AU2003245293A1 (en) Improved flight simulator
AU2003223405A1 (en) Technique for distributing sotware background
AU2003243058A1 (en) Methods for using the cd163 pathway for modulating an immune response
AU2003220381A1 (en) Polarimeter
AU2003263849A1 (en) Gace spacer
AU2002242175A1 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
AU2003278965A1 (en) Mechanism for implementing server-side pluglets
AU2003206210A1 (en) Educational block set
AU2003280450A1 (en) Projector
AU2003282335A1 (en) Firearm simulation device
AU2003244147A1 (en) Device for connecting two members
AU2003295702A1 (en) Signature simulator
AU2003284514A1 (en) Disc device
AU2003206743A1 (en) Cooking system
AUPS338802A0 (en) Simulator
AU2003264722A1 (en) Methods
AU2003282073A1 (en) Tight control device
AU2003259908A1 (en) Antenna-coupled microbolometer
AU2003205657A1 (en) Spacer
AU2003218992A1 (en) Set-top-box
AU2003236589A1 (en) Simulator

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 5, PAGE(S) 1100 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME BIOCEROS B.V. I.O., APPLICATION NO. 2003243058, UNDER INID (71) CORRECT THE NAME TO READ BIOCEROS B.V.; MACROZYME B.V.